Thermosensitive gel of polysaccharide from Ganoderma applanatum combined with paclitaxel for mice with 4T1 breast cancer.
10.19540/j.cnki.cjcmm.20200328.304
- Author:
Lan TANG
1
;
Zhuan-Feng ZHU
1
;
Li-Peng CAO
1
;
Miao SHEN
1
;
Yan GAO
1
;
Chao-Jie TU
1
;
Zhen-Hai ZHANG
2
;
Wei-Guang SHAN
1
Author Information
1. College of Pharmacy,Zhejiang University of Technology Hangzhou 310014,China.
2. Key Laboratory of New Drug Delivery System of Chinese Materia Medica,Jiangsu Provincial Academy of Chinese Medicine,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine Nanjing 210028,China.
- Publication Type:Journal Article
- Keywords:
breast cancer;
combination therapy;
paclitaxel;
polysaccharide from Ganoderma applanatum;
thermosensitive gel
- MeSH:
Animals;
Breast Neoplasms;
Cell Line, Tumor;
Ganoderma;
Mice;
Neoplasms;
Paclitaxel;
Poloxamer;
Polysaccharides
- From:
China Journal of Chinese Materia Medica
2020;45(11):2533-2539
- CountryChina
- Language:Chinese
-
Abstract:
Polysaccharide from Ganoderma applanatum has the activities of anti-tumor and enhancing immune function. There were no reports on antitumor effect of its intratumoral injection. In this study, the polysaccharide was extracted from G. applanatum by water extraction and alcohol precipitation, and purified by ceramic membrane after removing protein by Sevage method. The total polysaccharide content from G. applanatum(PGA)was about 63%. The combination of PGA and paclitaxel showed synergistic effect on cytotoxicity of 4 T1 cells at lower concentrations in vitro. In addition, the growth curve of 4 T1 cells showed that PGA could retard the growth of 4 T1 cells gradually. The PGA thermosensitive gel(PGA-TG)was prepared by using poloxamer 188 and 407. The gel temperature was 36 ℃, and the PGA-TG could effectively slow down the release rate of PGA in vitro. 4 T1 breast cancer-bearing mice were used as a model to evaluate the therapeutic effect of intratumoral injection of PGA combined with tail vein injection of nanoparticle albumin-bound paclitaxel(nab-PTX). In high and low dose PGA groups, each mice was given with 2.25, 1.125 mg PGA respectively, twice in total, and the dosage of paclitaxel was 15 mg·kg~(-1), once every 3 days, for a total of five times. The tumor inhibition rate was 29.65% in the high dose PGA-TG group, 58.58% in the nab-PTX group, 63.37% in low dose PGA-TG combined with nab-PTX group, and 68.10% in high dose PGA-TG combined with nab-PTX group respectively. The inhibitory effect in high dose PGA-TG group combined with nab-PTX on tumors was significantly higher than that in nab-PTX group(P<0.05). The results showed that paclitaxel therapy combined with intratumoral injection of PGA-TG could improve the therapeutic effect for 4 T1 mice and reduce the side effects of chemotherapy.
